EA201892144A1 - Конденсированные гексациклические производные имидазола в качестве модуляторов активности tnf - Google Patents
Конденсированные гексациклические производные имидазола в качестве модуляторов активности tnfInfo
- Publication number
- EA201892144A1 EA201892144A1 EA201892144A EA201892144A EA201892144A1 EA 201892144 A1 EA201892144 A1 EA 201892144A1 EA 201892144 A EA201892144 A EA 201892144A EA 201892144 A EA201892144 A EA 201892144A EA 201892144 A1 EA201892144 A1 EA 201892144A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- disorders
- derivatives
- imidazol
- tnf activity
- activity modulator
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 102000057041 human TNF Human genes 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 230000003040 nociceptive effect Effects 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16163577 | 2016-04-01 | ||
| PCT/EP2017/057768 WO2017167995A1 (en) | 2016-04-01 | 2017-03-31 | Fused hexacyclic imidazole derivatives as modulators of tnf activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201892144A1 true EA201892144A1 (ru) | 2019-04-30 |
Family
ID=55650325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201892144A EA201892144A1 (ru) | 2016-04-01 | 2017-03-31 | Конденсированные гексациклические производные имидазола в качестве модуляторов активности tnf |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10766906B2 (enExample) |
| EP (1) | EP3436456B1 (enExample) |
| JP (1) | JP6968089B2 (enExample) |
| CN (1) | CN109219609B (enExample) |
| BR (1) | BR112018069937A2 (enExample) |
| CA (1) | CA3018992A1 (enExample) |
| EA (1) | EA201892144A1 (enExample) |
| WO (1) | WO2017167995A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
| CA3117344A1 (en) * | 2018-10-24 | 2020-04-30 | UCB Biopharma SRL | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
| JP2025540024A (ja) | 2022-11-23 | 2025-12-11 | フォワード セラピューティクス， インコーポレイテッド | ＴＮＦ－α活性の調節因子 |
| TW202513567A (zh) * | 2023-06-09 | 2025-04-01 | 大陸商上海翰森生物醫藥科技有限公司 | 五環類衍生物抑制劑、其製備方法與應用 |
| WO2025038927A1 (en) | 2023-08-16 | 2025-02-20 | Raythera, Inc. | Modulators of tnf alpha activity and uses thereof |
| CN121925420A (zh) * | 2023-09-29 | 2026-04-24 | 赛诺菲 | 作为tnf活性的调节剂的桥联五环咪唑衍生物的制备、中间体及其制备 |
| WO2025162456A1 (en) * | 2024-01-31 | 2025-08-07 | Intelligen Therapeutics | Macrocyclic compound, pharmaceutical composition and use thereof |
| WO2025201449A1 (zh) * | 2024-03-27 | 2025-10-02 | 海思科医药集团股份有限公司 | 一种杂环衍生物及其在医药上的应用 |
| WO2025212627A1 (en) | 2024-04-03 | 2025-10-09 | Forward Therapeutics, Inc. | Modulators of tnf-alpha activity |
| WO2025244936A1 (en) * | 2024-05-20 | 2025-11-27 | Forward Therapeutics, Inc. | Modulators of tnf-alpha activity |
| WO2026012303A1 (en) * | 2024-07-09 | 2026-01-15 | Hangzhou Highlightll Pharmaceutical Co., Ltd | NOVEL BENZO [4, 5] IMIDAZO COMPOUNDS AS TNFα MODULATORS |
| WO2026022134A1 (en) * | 2024-07-23 | 2026-01-29 | Sanofi | Novel aminocarbonylation processes |
| WO2026044218A1 (en) * | 2024-08-23 | 2026-02-26 | Synnovation Therapeutics, Inc. | Heterocyclic compounds as modulators of tnfa activity |
| WO2026055519A1 (en) | 2024-09-06 | 2026-03-12 | Rapt Therapeutics, Inc. | Fused ring imidazole compounds |
| WO2026064303A1 (en) * | 2024-09-17 | 2026-03-26 | Synnovation Therapeutics, Inc. | HETEROCYCLIC COMPOUNDS AS MODULATORS OF TNFα ACTIVITY |
| WO2026068677A1 (en) | 2024-09-27 | 2026-04-02 | Sanofi | Processes for the preparation of fused pentacyclic imidazoles and intermediates |
| WO2026086865A1 (zh) * | 2024-10-24 | 2026-04-30 | 宜昌人福药业有限责任公司 | 小分子TNF-α抑制剂及其用途 |
| WO2026112363A1 (en) | 2024-11-21 | 2026-05-28 | Rapt Therapeutics, Inc. | Fused heterocyclic aromatic compounds and uses thereof |
| WO2026145577A1 (zh) * | 2024-12-31 | 2026-07-09 | 无锡奕拓医药科技有限责任公司 | 桥环类化合物、其药物组合物及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004087720A1 (en) | 2003-03-10 | 2004-10-14 | Pfizer Inc. | Phosphate/sulfate ester compounds and pharmaceutical compositions for inhibiting protein interacting nima (pin1) |
| TW200615273A (en) * | 2004-11-10 | 2006-05-16 | Nicholas Piramal India Ltd | Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha |
| DE102008030206A1 (de) | 2008-06-25 | 2009-12-31 | Bayer Schering Pharma Aktiengesellschaft | 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung |
| TW201242953A (en) | 2011-03-25 | 2012-11-01 | Bristol Myers Squibb Co | Imidazole prodrug LXR modulators |
| ES2576298T3 (es) | 2011-06-20 | 2016-07-06 | Vertex Pharmaceuticals Incorporated | Ésteres de fosfato de inhibidores de girasa y topoisomerasa |
| CA2874303C (en) * | 2012-06-11 | 2020-10-13 | Ucb Biopharma Sprl | Tnf -alpha modulating benz imidazoles |
| GB201212513D0 (en) | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| ES2689429T3 (es) | 2012-07-13 | 2018-11-14 | Ucb Biopharma Sprl | Derivados de imidazopiridina como moduladores de actividad de TNF |
| GB201321728D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321729D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321730D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| ES2885432T3 (es) * | 2014-10-03 | 2021-12-13 | Ucb Biopharma Sprl | Derivados de imidazol pentacíclicos condensados |
| PH12019502182B1 (en) * | 2017-04-25 | 2024-01-31 | Sanofi Sa | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
-
2017
- 2017-03-31 CN CN201780033406.1A patent/CN109219609B/zh not_active Expired - Fee Related
- 2017-03-31 EA EA201892144A patent/EA201892144A1/ru unknown
- 2017-03-31 CA CA3018992A patent/CA3018992A1/en active Pending
- 2017-03-31 EP EP17713705.6A patent/EP3436456B1/en active Active
- 2017-03-31 JP JP2018551326A patent/JP6968089B2/ja active Active
- 2017-03-31 US US16/086,414 patent/US10766906B2/en active Active
- 2017-03-31 WO PCT/EP2017/057768 patent/WO2017167995A1/en not_active Ceased
- 2017-03-31 BR BR112018069937A patent/BR112018069937A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US10766906B2 (en) | 2020-09-08 |
| EP3436456B1 (en) | 2021-11-17 |
| CA3018992A1 (en) | 2017-10-05 |
| WO2017167995A1 (en) | 2017-10-05 |
| JP6968089B2 (ja) | 2021-11-17 |
| CN109219609B (zh) | 2022-02-01 |
| US20190100526A1 (en) | 2019-04-04 |
| CN109219609A (zh) | 2019-01-15 |
| JP2019512532A (ja) | 2019-05-16 |
| EP3436456A1 (en) | 2019-02-06 |
| BR112018069937A2 (pt) | 2019-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201992407A1 (ru) | Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf | |
| EA202090019A1 (ru) | Спироциклические индолины в качестве модуляторов il-17 | |
| EA201790734A1 (ru) | Конденсированные пентациклические производные имидазола | |
| EA201401350A1 (ru) | Бензимидазолы, модулирующие tnf-альфа | |
| EA201792688A1 (ru) | Производные бензоксазинона и его аналоги в качестве модуляторов активности tnf | |
| EA201892153A1 (ru) | Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf | |
| EA201792686A1 (ru) | Производные индазола в качестве модуляторов активности tnf | |
| EA201500130A1 (ru) | Производные имидазопиридина в качестве модуляторов активности tnf | |
| EA201500133A1 (ru) | Производные имидазопиразина в качестве модуляторов активности tnf | |
| EA201892142A1 (ru) | Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf | |
| BR112016012990A2 (pt) | Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf | |
| EA201990598A1 (ru) | Высококонцентрированные низковязкие препараты ингибирующего masp-2 антитела, наборы и способы | |
| EP3573658A4 (en) | ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR TREATMENT OF ACTIVE PSORIATIC ARTHRITIS | |
| BR112018069937A2 (pt) | derivados de imidazol hexacíclicos fundidos como moduladores de atividade do tnf | |
| EA201992083A1 (ru) | Модуляторы соматостатина и их применения | |
| EP3898617A4 (en) | TARGETED DOSAGE FOR THE TREATMENT OF COMPLEMENT INDUCED DISORDERS | |
| BR112016013018A2 (pt) | Derivados heteroaromáticos bicíclicos fundidos como moduladores de atividade de tnf | |
| BR112016012997A2 (pt) | Derivados de benzimidazóis tricíclicos fundidos como moduladores de atividade de tnf | |
| MX390120B (es) | Moduladores de la somatostatina y usos de los mismos. | |
| BR112016011483A2 (pt) | Derivados de imidazotriazina como moduladores de atividade de tnf | |
| BR112016012258A2 (pt) | Derivados de tetra-hidrobenzimidazol como moduladores de atividade de tnf | |
| BR112016012261A2 (pt) | Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| EA201890245A1 (ru) | Замещенные 4-азаиндолы и их применение в качестве модуляторов рецептора glun2b | |
| EA201991898A1 (ru) | Двойные ингибиторы magl и faah |